MedTrace Logo

Interferon Lambda Therapy for COVID-19

NCT04388709 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-02-26

No results posted yet for this study

Summary

The main purpose of this research study is to test the safety and effectiveness of an investigational drug peginterferon lambda-1a in treating COVID-19.

Conditions

Interventions

DRUG

Peginterferon Lambda-1A

Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once

Sponsors & Collaborators

Principal Investigators

  • Thomas Marron, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2021-02-05
Completion
2021-02-05
FDA Drug
Yes

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04388709 on ClinicalTrials.gov